Global Meningococcal Group B Vaccine Market Size By Type (Bexsero, Trumenba), By Application (Public, Private), By Region, And Segment Forecasts, 2023 to 2032

The Global Meningococcal Group B Vaccine Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 4.4 billion by 2031, growing at a CAGR of 9.6% during the forecast period from 2023 to 2031. This growth is driven by the increasing incidence of invasive meningococcal disease (IMD), rising awareness of immunization programs, and proactive government initiatives to prevent outbreaks. The market is also benefitting from technological advancements in vaccine development and the expansion of immunization coverage in both developed and emerging markets.

Drivers:

1. Rising Prevalence of Invasive Meningococcal Disease:

The growing number of meningococcal infections globally, particularly among infants, adolescents, and young adults, is a key driver. Meningococcal Group B is one of the most prevalent and deadly strains, contributing significantly to overall disease burden.

2. Increasing Immunization Coverage and Awareness:

Widespread public health campaigns and government-sponsored vaccination programs have elevated awareness among the general population, thereby fueling demand for Group B vaccines.

3. Technological Advancements in Vaccine Formulation:

Improvements in recombinant protein-based vaccines and novel adjuvant systems have enhanced the safety, efficacy, and duration of protection provided by Meningococcal Group B vaccines.

Restraints:

1. High Cost of Vaccines:

The relatively high price of Meningococcal Group B vaccines, particularly in countries without subsidized healthcare systems, poses a significant challenge to widespread adoption.

2. Limited Access in Low-Income Regions:

Despite growing awareness, access to Group B vaccines remains limited in certain low- and middle-income countries due to infrastructure and cost constraints.

Opportunity:

1. Expansion in Emerging Markets:

Emerging economies are increasingly investing in public health infrastructure, offering opportunities for market expansion as these countries adopt broader immunization programs.

2. R&D and Pipeline Development:

Ongoing research in protein subunit vaccines and broader serogroup protection solutions is expected to generate innovative products that address current limitations and create new revenue streams.

Market by System Type Insights:

The Multicomponent Protein-Based Vaccine segment accounted for the largest share in 2023. Vaccines like 4CMenB (Bexsero) and rLP2086 (Trumenba) dominate the market due to their proven efficacy in inducing immune responses against multiple Group B strains. These vaccines are being widely adopted in national immunization schedules, especially in high-risk regions.

Market by End-Use Insights:

The Pediatric and Adolescent Population segment remains the largest consumer base in 2023. Due to the high vulnerability of infants and teenagers to meningococcal infections, this demographic represents the primary target group for immunization programs. Routine vaccination schedules in many countries now include Group B vaccines for this age group.

Market by Regional Insights:

North America led the global Meningococcal Group B Vaccine Market in 2023, supported by strong healthcare infrastructure, high awareness levels, and government-backed vaccination initiatives. Meanwhile, Asia-Pacific is expected to witness the fastest growth, driven by increasing healthcare investments, large population base, and expanding vaccine coverage.

Competitive Scenario:

Key players in the global market include GlaxoSmithKline plc, Pfizer Inc., Sanofi S.A., Serum Institute of India, and Biomed Pvt. Ltd. These companies are focusing on expanding production capabilities, conducting clinical trials, and collaborating with public health agencies to enhance vaccine availability. Notable recent developments include:

2024: Pfizer launched an updated version of its Trumenba vaccine, optimized for broader strain coverage.

2023: GSK received approval in multiple new countries for the pediatric use of Bexsero.

2022: Serum Institute of India announced the development of a low-cost MenB vaccine targeting African and South Asian markets.

Scope of Work – Global Meningococcal Group B Vaccine Market

Key Market Developments:

February 2024: GSK’s Bexsero approved in Brazil for use in children under 1 year.

August 2023: Pfizer received FDA priority review for expanded indication of Trumenba.

April 2022: Sanofi partnered with GAVI to improve MenB vaccine distribution in Africa.

FAQs:

1) What is the current market size of the Global Meningococcal Group B Vaccine Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Meningococcal Group B Vaccine Market?

The major growth driver is the rising incidence of invasive meningococcal disease and increased immunization coverage.

3) Which is the largest region during the forecast period in the Global Meningococcal Group B Vaccine Market?

North America held the largest market share in 2023.

4) Which segment accounted for the largest market share in Global Meningococcal Group B Vaccine Market?

The Multicomponent Protein-Based Vaccine segment accounted for the largest market share.

5) Who are the key market players in the Global Meningococcal Group B Vaccine Market?

Key players include GlaxoSmithKline, Pfizer, Sanofi, Serum Institute of India, and Biomed Pvt. Ltd.